<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://pepsreview.com/articles/thailand-makes-glp-1-injections-prescription-only</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-15</news:publication_date>
      <news:title><![CDATA[Thailand Makes GLP-1 Weight-Loss Injection Pens Prescription-Only]]></news:title>
      <news:keywords>Thailand GLP-1 prescription, semaglutide regulation, weight-loss injection pens, Thai FDA, counterfeit peptides, GLP-1 enforcement, prescription-only</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/counterfeit-semaglutide-peptide-hospitalizes-new-zealand-user</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-15</news:publication_date>
      <news:title><![CDATA[Counterfeit 'Peptide' Containing Heavy Semaglutide Dose Puts New Zealand User in Hospital]]></news:title>
      <news:keywords>counterfeit semaglutide, peptide safety, unregulated injectables, GLP-1 counterfeit, independent testing, certificate of analysis, peptide verification</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/novo-nordisk-rebrands-as-novo-glp-1-strategic-reset</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-15</news:publication_date>
      <news:title><![CDATA[Novo Nordisk Rebrands as 'Novo' in Strategic Reset of the GLP-1 Market Battle]]></news:title>
      <news:keywords>Novo Nordisk rebrand, Novo, GLP-1 market, Wegovy, Ozempic, Zepbound competition, semaglutide, peptide safety</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/fda-glp-1-green-list-faces-shutdown-call-over-counterfeit-api-risk</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-14</news:publication_date>
      <news:title><![CDATA[FDA GLP-1 'Green List' Faces Shutdown Call Over Counterfeit API Risk]]></news:title>
      <news:keywords>GLP-1, FDA Green List, counterfeit semaglutide, API imports, peptide testing, tirzepatide, supply chain, Import Alert 66-80</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/saxenda-users-join-naion-litigation-vision-loss-claims-expand-liraglutide</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-14</news:publication_date>
      <news:title><![CDATA[Saxenda Users Join NAION Litigation as Vision-Loss Claims Expand to Liraglutide]]></news:title>
      <news:keywords>Saxenda lawsuit, liraglutide NAION, GLP-1 litigation, vision loss, Novo Nordisk, NAION claims, incretin safety, drug safety news</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/australian-patient-torn-oesophagus-unapproved-peptide</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-14</news:publication_date>
      <news:title><![CDATA[Australian Patient Suffers Torn Oesophagus After Using Unapproved Peptide]]></news:title>
      <news:keywords>peptide safety Australia, unapproved peptide, torn oesophagus, TGA warning, gray market peptides, peptide injury, research peptide testing</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/zepbound-lawsuits-2026-who-qualifies-file-claim</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-14</news:publication_date>
      <news:title><![CDATA[Zepbound Lawsuits in 2026: Who May Qualify to File and What Courts Are Weighing]]></news:title>
      <news:keywords>Zepbound lawsuit, GLP-1 litigation, tirzepatide lawsuit, Eli Lilly, gastroparesis lawsuit, GLP-1 MDL, who qualifies, drug injury claim</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/empower-pharmacy-lawsuit-widens-2026-claims-compounded-glp-1s</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-13</news:publication_date>
      <news:title><![CDATA[Empower Pharmacy Lawsuit Widens as 2026 Claims Target Compounded GLP-1s]]></news:title>
      <news:keywords>Empower Pharmacy lawsuit, compounded semaglutide, compounded tirzepatide, 503B outsourcing facility, GLP-1 litigation, FDA warning letter, peptide testing</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/fda-coordinated-enforcement-sweep-targets-peptide-sellers</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-13</news:publication_date>
      <news:title><![CDATA[FDA Runs Coordinated Enforcement Sweep Targeting Peptide Sellers]]></news:title>
      <news:keywords>FDA enforcement, peptide sellers, FDA sweep, unapproved peptides, peptide regulation, GLP-1 enforcement, peptide import screening</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/verification-tools-proliferate-as-peptide-buyers-demand-proof</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-13</news:publication_date>
      <news:title><![CDATA[Verification Tools Proliferate as Peptide Buyers Demand Proof Behind Claims]]></news:title>
      <news:keywords>peptide claims verification, evidence checker, peptide purity testing, COA verification, research peptide market, peptide quality control, third party testing</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/market-intelligence-index-tracks-100-peptide-vendors-112000-public-coa-records</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-13</news:publication_date>
      <news:title><![CDATA[Market Intelligence Index Tracks 100+ Peptide Vendors and 112,000 Public COA Records]]></news:title>
      <news:keywords>peptide market intelligence, peptide vendor comparison, COA records, peptide prices, research peptide market, peptide testing, vendor transparency</news:keywords>
    </news:news>
  </url>
</urlset>